zanamivir has been researched along with Disease Models, Animal in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 13 (48.15) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Li, YH; Li, ZR; Liu, ZY; Shao, HY; Wang, B; Yi, H; You, XF; Zhao, LX | 1 |
| Kakuta, M; Kubo, S; Tokumitsu, A; Tomozawa, T; Yamashita, M | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Kakuta, M; Kubo, S; Tanaka, M; Tobiume, S; Tomozawa, T; Yamashita, M | 1 |
| Abed, Y; Boivin, G; Pizzorno, A; Rhéaume, C | 1 |
| Hurt, AC; Margo, K; Morton, DA; Mosse, J; Oh, DY; Panozzo, J; Piedrafita, D | 1 |
| Graf, C; Graf, P; Grassauer, A; Kirchoff, N; Koller, C; König-Schuster, M; Morokutti-Kurz, M; Nakowitsch, S; Prieschl-Grassauer, E; Reutterer, B; Seifert, JM; Unger, H | 1 |
| Gabor, KA; Goody, MF; Jurcyzszak, D; Kim, CH; Longfellow, JR; Millard, PJ; Sullivan, C | 1 |
| Osterhaus, AD; Pistoor, F; Simon, J; Stittelaar, KJ; Tisdale, M; van Amerongen, G; van Lavieren, RF | 1 |
| Govorkova, EA; Ilyushina, NA; Rehg, JE; Seiler, JP; Webster, RG | 1 |
| Barr, IG; Hurt, AC; Lowther, S; Middleton, D | 1 |
| Albrecht, RA; García-Sastre, A; Kaminski, M; Kochs, G; Medina, RA; Palese, P; Philipp, J; Rubbenstroth, D; Schwalm, F; Seibert, CW; Staeheli, P; Stertz, S | 1 |
| Yamashita, M | 1 |
| Kakuta, M; Kubo, S; Yamashita, M | 1 |
| Horimoto, T; Imai, H; Kakugawa, S; Kawaoka, Y; Kiso, M; Le, MT; Noda, T; Ozawa, M; Takahashi, K | 1 |
| Kaminski, MM; Ohnemus, A; Rubbenstroth, D; Staeheli, P | 1 |
| Sauerbrei, A; Ulbricht, A; Wutzler, P | 1 |
| Blanco, J; Curtis, S; Ottolini, M; Peterson, L; Porter, D; Prince, G | 1 |
| Elias, S; Fenton, R; Herlocher, ML; Klimov, A; Monto, AS; Ohmit, SE; Truscon, R | 1 |
| Arai, M; Honda, T; Kaneko, S; Masuda, T; Yamashita, M; Yoshida, S | 1 |
| Eichelberger, MC; Ottolini, MG; Prince, GA | 1 |
| Govorkova, EA; Herlocher, LM; Hoffmann, E; Matrosovich, MN; Monto, AS; Webster, RG; Yen, HL | 1 |
| Dyason, JC; Jin, B; Kok, GB; Oliver, SW; Pegg, MS; Smythe, ML; Van Phan, T; von Itzstein, M; White, HF; Wu, WY | 1 |
| Bischofberger, N; Chen, MS; Escarpe, PA; Huffman, JH; Jakeman, KJ; Kim, CU; Lacy, SA; Lew, W; Li, W; Mendel, DB; Merson, J; Sidwell, RW; Sweet, C; Tai, CY; Williams, MA; Zhang, L | 1 |
| Bailey, KW; Barnard, DL; Huffman, JH; Kim, CU; Morrison, A; Sidwell, RW; Syndergaard, T; Wong, MH | 1 |
| Bricaire, F | 1 |
| Bush, K; Goloubeva, OG; Govorkova, EA; Leneva, IA; Webster, RG | 1 |
1 review(s) available for zanamivir and Disease Models, Animal
| Article | Year |
|---|---|
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Guanidines; Humans; Influenza, Human; Mice; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pandemics; Prodrugs; Pyrans; Rats; Sialic Acids; Zanamivir | 2010 |
26 other study(ies) available for zanamivir and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
Topics: Administration, Oral; Animals; Cell Line; Disease Models, Animal; Dogs; Drug Design; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Infusions, Parenteral; Inhibitory Concentration 50; Mice; Ribavirin; Zanamivir | 2007 |
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Treatment Outcome; Zanamivir | 2010 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
Topics: Administration, Intravenous; Animals; Antiviral Agents; Disease Models, Animal; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Mice; Mice, Inbred BALB C; Pyrans; Sialic Acids; Zanamivir | 2013 |
Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.
Topics: Animals; Antiviral Agents; Body Weight; Disease Models, Animal; Drug Therapy, Combination; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Lung; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome; Viral Load; Zanamivir | 2014 |
Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
Topics: Administration, Inhalation; Animals; Antiviral Agents; Disease Models, Animal; Drug Carriers; Ferrets; Guanidines; Orthomyxoviridae Infections; Placebos; Powders; Pyrans; Sialic Acids; Zanamivir | 2015 |
The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Carrageenan; Disease Models, Animal; Dogs; Humans; Influenza A virus; Influenza A Virus, H7N7 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Mice; Orthomyxoviridae Infections; Treatment Outcome; Zanamivir | 2015 |
Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Humans; Influenza A virus; Neutrophils; Orthomyxoviridae Infections; Zanamivir; Zebrafish | 2017 |
Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Macaca; Male; Zanamivir | 2008 |
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Topics: Animals; Antiviral Agents; Cell Line; Crystallography; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Kidney; Male; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Structure, Tertiary; Recombinant Proteins; Zanamivir | 2010 |
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; DNA Mutational Analysis; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Zanamivir | 2010 |
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.
Topics: Animals; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guinea Pigs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2010 |
[In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
Topics: Administration, Intranasal; Animals; Antiviral Agents; Cells, Cultured; Delayed-Action Preparations; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Pandemics; Viral Load; Virus Replication; Zanamivir | 2010 |
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Asparagine; Disease Models, Animal; Drug Resistance, Viral; Female; Ferrets; Influenza A Virus, H5N1 Subtype; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Point Mutation; Rodent Diseases; Serine; Survival Analysis; Treatment Outcome; Viral Proteins; Virulence; Virulence Factors; Virus Replication; Zanamivir | 2011 |
Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Guinea Pigs; Influenza A Virus, H1N1 Subtype; Molecular Sequence Data; Mutant Proteins; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Virulence; Virulence Factors; Zanamivir | 2013 |
Semi-quantitative detection of viral RNA in influenza A virus-infected mice for evaluation of antiviral compounds.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Disease Models, Animal; Female; Guanidines; Influenza A virus; Lung; Mice; Mice, Inbred BALB C; Nasopharynx; Orthomyxoviridae Infections; Pyrans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sialic Acids; Trachea; Zanamivir | 2003 |
Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.
Topics: Acetamides; Animals; Antiviral Agents; Disease Models, Animal; Drug Therapy, Combination; Glucocorticoids; Guanidines; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Rats; Sialic Acids; Sigmodontinae; Triamcinolone Acetonide; Zanamivir | 2003 |
Assessment of development of resistance to antivirals in the ferret model of influenza virus infection.
Topics: Amantadine; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guanidines; Hemagglutination Inhibition Tests; Influenza A virus; Male; Orthomyxoviridae Infections; Point Mutation; Pyrans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Sialic Acids; Zanamivir | 2003 |
Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Guanidines; Influenza A virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Zanamivir | 2003 |
Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor.
Topics: Albuterol; Animals; Anti-Inflammatory Agents; Antiviral Agents; Bronchodilator Agents; Disease Models, Animal; Female; Glucocorticoids; Guanidines; Humans; Influenza A virus; Influenza, Human; Male; Neuraminidase; Pyrans; Respiration Disorders; Sialic Acids; Sigmodontinae; Triamcinolone Acetonide; Zanamivir | 2004 |
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
Topics: Acetamides; Amino Acid Substitution; Animals; Cell Line; Coculture Techniques; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Tolerance; Enzyme Inhibitors; Enzyme Stability; Female; Ferrets; Genetic Variation; Guanidines; Kinetics; Mutagenesis, Site-Directed; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Recombination, Genetic; Sialic Acids; Temperature; Virus Replication; Zanamivir | 2005 |
Rational design of potent sialidase-based inhibitors of influenza virus replication.
Topics: Animals; Antiviral Agents; Cell Line; Computer-Aided Design; Disease Models, Animal; Drug Design; Female; Ferrets; Guanidines; Humans; Influenza A virus; Influenza, Human; Mice; Models, Molecular; Neuraminidase; Pyrans; Sheep; Sialic Acids; Viral Plaque Assay; Virus Replication; Zanamivir | 1993 |
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Topics: Acetamides; Administration, Oral; Amines; Animals; Antiviral Agents; Disease Models, Animal; Female; Ferrets; Guanidines; Influenza A virus; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Rats; Rats, Sprague-Dawley; Sialic Acids; Virus Replication; Zanamivir | 1998 |
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Topics: Acetamides; Administration, Intranasal; Administration, Oral; Amines; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Lung Diseases; Mice; Mice, Inbred BALB C; Molecular Structure; Neuraminidase; Oseltamivir; Pyrans; Ribavirin; Sialic Acids; Zanamivir | 1998 |
[Influenza: new therapeutic perspectives].
Topics: Administration, Intranasal; Animals; Antiviral Agents; Disease Models, Animal; Guanidines; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Mice; Prospective Studies; Pyrans; Rodentia; Sialic Acids; Vaccination; Zanamivir | 1998 |
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Brain; Cyclopentanes; Disease Models, Animal; Dogs; Female; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir | 2001 |